Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies (Q36836080)
Jump to navigation
Jump to search
scientific article published on 3 August 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies |
scientific article published on 3 August 2009 |
Statements
1 reference
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies (English)
1 reference
Owen A O'Connor
1 reference
Steven Horwitz
1 reference
Carol Portlock
1 reference
Craig H Moskowitz
1 reference
Ellen Neylon
1 reference
Jill Mastrella
1 reference
Rachel Hamelers
1 reference
Barbara Macgregor-Cortelli
1 reference
Molly Patterson
1 reference
Venkatraman E Seshan
1 reference
Frank Sirotnak
1 reference
Martin Fleisher
1 reference
Diane R Mould
1 reference
Mike Saunders
1 reference
3 August 2009
1 reference
1 reference
4357-4364
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference